Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism

and May Evade Common Drug Resistance Mechanisms

Research Supports Current Clinical Development of SNS-595 in AML and

Ovarian Cancer and Potential in Additional Indications

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 in combination with cytarabine in relapsed/refractory acute myeloid leukemia (AML) are both ongoing.

"Data presented today provide important new insights into SNS-595's mechanism as a site-selective DNA intercalator and topoisomerase poison with selectivity for proliferating cells. Through its unique chemical structure and molecular mechanism, SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer. "Taken together, these data support our ongoing clinical trials of SNS-595 in platinum-resistant ovarian cancer and acute myeloid leukemia, and provide compelling evidence for future studies of SNS-595 in indications such as breast cancer where topoisomerase II poisons are active."

Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversi
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... N.J., March 27 Zydus Pharmaceuticals announced today that ... and Drug Administration (FDA) for its Abbreviated New Drug ... and 200mg. This product is available for immediate ... patients 10 years old or older with partial onset ...
... Michigan, there are not enough jobs in manufacturing and ... to overshadow supply is health care, particularly physicians.The health ... difficulty of becoming a doctor have led to a ... projected to get worse, according to the Michigan State ...
... Stats show safety programs need to be extended to others ... (HealthDay News) -- Only one-third of people killed in fatal ... report shows. , The other two-thirds of victims are passengers, ... to the AAA Foundation for Traffic Safety. , "For every ...
... Women,s Voices for the Health Care We NeedNEW YORK, March ... debate the merits and costs of health reform, women around ... our families. For many women and our families, health reform ... York City will speak out publicly about the problems they ...
... of a program established in Uganda last year, the ... (HVO) have again partnered to launch a new hematology ... Empresa De Seguros De Salud (EsSalud). The goal of ... clinicians, laboratory technicians, technologists, and students. This training will ...
... unlocks the virus from latent state , , FRIDAY, March 27 ... in the ongoing quest for a treatment, and possibly a ... as VP16 is apparently responsible for pushing herpes out of ... , Experts estimate that 70 percent to 90 percent of ...
Cached Medicine News:Health News:As Physician Shortage Looms, Recognize Your Doctor On March 30, National Doctors' Day 2Health News:Most Fatalities in Teen Crashes Are Not the Drivers 2Health News:Women's Speak-Out for Action on Health Care Reform 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 3Health News:Treatment Target for Herpes Pinpointed 2
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Emdeon (NYSE: EM ), a leading provider of healthcare ... participate in the Piper Jaffray Annual Health Care Conference to be ... The "fireside chat", featuring Tracy Bahl, executive chairman, will begin at ... live audio webcast will be available in the Investors section of ...
... , BURLINGTON, Mass., Nov. 17 Palomar Medical ... announce the immediate availability of the Groove Optic for ... significant advancement in fractional ablative skin resurfacing by creating ... ablative tissue coverage while preserving the benefits of fractional ...
Cached Medicine Technology:New! The Groove Optic(TM) for the Lux2940(TM): A Breakthrough in Fractional Skin Resurfacing 2New! The Groove Optic(TM) for the Lux2940(TM): A Breakthrough in Fractional Skin Resurfacing 3
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... is a fully automated genetic analysis system. ... with a patented linear polyacrylamide (LPA) gel, ... voltage program, and analyzes the data. Software ... and even customize automated data assessment. All ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
Medicine Products: